Teva’s ($TEVA) Pivot to Growth hits high Gear: Q4 results and beyond
Teva is officially a biopharma compounder now
Introduction
Teva Pharmaceutical has officially entered its “Acceleration Phase.” Following the release of its Q4 and full-year 2025 results, it is clear that the company is no longer just a generics giant in recovery—it has successfully pivoted into a high-margin, innovative biopharma powerhouse. The narrative surrounding Teva has shifted from stabiliz…
